Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Nkarta, Inc.
  6. Summary
    NKTX   US65487U1088

NKARTA, INC.

(NKTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
27.24(c) 27.47(c) 27.24(c) 29.42(c) 30.28 Last
846 448 213 561 440 542 214 452 161 306 Volume
-0.07% +0.84% -0.84% +8.00% +2.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -87,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -11,5x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -118 M - -
Net Debt 2022 - - -
P/E ratio 2022 -9,09x
Yield 2022 -
Capitalization 996 M 996 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 116
Free-Float 89,1%
More Financials
Company
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40... 
More about the company
Ratings of Nkarta, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about NKARTA, INC.
09/14NKARTA : to Participate at Upcoming Investor Conference
AQ
08/13NKARTA : Posts Narrower Q2 Loss; Files for Up to $500 Million Mixed-Securities S..
MT
08/12NKARTA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/12NKARTA : Reports Second Quarter 2021 Financial Results and Business Progress (Fo..
PU
08/12NKARTA, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/12Nkarta, Inc. Announces Unaudited Earnings Results for the Three Months and Si..
CI
08/12NKARTA : Reports Second Quarter 2021 Financial Results and Business Progress
AQ
08/03OYSTER POINT PHARMA : Names Donald Santel as Non-Executive Chairman
MT
07/16NKARTA : Oppenheimer Initiates Coverage on Nkarta With Outperform Rating, $75 Pr..
MT
07/14NKARTA : Signs Lease Agreement for Facility in South San Francisco
MT
07/14NKARTA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
07/14NKARTA : Establishes New Combined NK Cell Therapy Manufacturing Facility / Compa..
PU
07/14NKARTA : Establishes New Combined NK Cell Therapy Manufacturing Facility / Compa..
AQ
07/14Nkarta, Inc. Signs Lease Agreement for a Facility to Support Research and Dev..
CI
06/29NKARTA : Cantor Fitzgerald Adjusts Nkarta PT to $71 From $78, Maintains Overweig..
MT
More news
News in other languages on NKARTA, INC.

- No features available -

More news
Analyst Recommendations on NKARTA, INC.
More recommendations
Chart NKARTA, INC.
Duration : Period :
Nkarta, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NKARTA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 30,28 $
Average target price 74,80 $
Spread / Average Target 147%
EPS Revisions
Managers and Directors
Paul J. Hastings President, Chief Executive Officer & Director
Nadir Mahmood Chief Financial & Business Officer
Ali Behbahani Chairman
Ralph Brandenberger Senior Vice President-Technical Operations
James Trager Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
NKARTA, INC.-50.74%968
GILEAD SCIENCES, INC.23.17%89 973
BIONTECH SE335.78%85 800
REGENERON PHARMACEUTICALS34.96%67 787
WUXI APPTEC CO., LTD.28.41%64 886
VERTEX PHARMACEUTICALS-20.09%48 996